$0.3725
-0.03-6.29%
At close: -
$0.3725
0.000.00%
After Hours: Apr 4, 4:00 PM EDT
Comments
Loading...
Generation Bio Insider Trading Activity | NASDAQ:GBIO | Benzinga
Track the latest Generation Bio insider trading activity. Stay informed on recent buys, sells, and market impact for Generation Bio stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Generation Bio Co Insiders Doing?
Insiders have report no purchases/sales in the last 30 days.
Notable Recent Insider Buys and Sales
- On January 14, 2025, Anthony Quinn, the company's - purchased 210.79K shares for $0.96 each.
Ownership Statistics for Generation Bio Co
Shares Outstanding
67.008M
Insider Shares Owned
3.863M
Insider Percentage Owned
5.77%
Institutional Shares Held
24.597M
Institutional Percentage Held
36.7%
| Jan 14, 2025 | Anthony Quinn | — | 210.79K | $0.96 | $203.21K | BUY | 238.20% | 299.29K | Jan 10 - Jan 13 | View |
| Jul 03, 2024 | Antoinette Paone | CHIEF OPERATING OFFICER | -6.72K | $2.74 | -$18.41K | SELL | -32.73% | 13.81K | Jul 01 | View |
| Jan 03, 2024 | Antoinette Paone | CHIEF OPERATING OFFICER | -2.44K | $1.62 | -$3.96K | SELL | -29.55% | 5.83K | Jan 02 | View |
| Jan 03, 2024 | Phillip Samayoa | CHIEF STRATEGY OFFICER | -2.44K | $1.62 | -$3.96K | SELL | -2.23% | 107.26K | Jan 02 | View |
| Dec 11, 2023 | Dannielle Appelhans | — | 8.00K | $1.79 | $14.34K | BUY | ∞ | 7.36K | Dec 08 | View |
| Dec 06, 2023 | Dannielle Appelhans | — | 12.00K | $1.50 | $18.00K | BUY | ∞ | 12.00K | Dec 04 | View |
| Dec 05, 2023 | Anthony Quinn | — | 88.50K | $1.41 | $124.78K | BUY | 121.50% | 161.33K | Dec 01 | View |
| Dec 05, 2023 | Charles Rowland Jr | — | 342.96K | $1.39 | $477.78K | BUY | 178.81% | 534.76K | Dec 01 - Dec 04 | View |
| Dec 05, 2023 | William Donald Nicholson | — | 100.00K | $1.44 | $144.00K | BUY | 88.05% | 213.58K | Dec 01 | View |
| Aug 25, 2023 | Antoinette Paone | CHIEF OPERATING OFFICER | -3.12K | $4.93 | -$15.36K | SELL | -51.67% | 2.91K | Aug 23 | View |
| Jul 05, 2023 | Phillip Samayoa | CHIEF STRATEGY OFFICER | -3.12K | $5.29 | -$16.48K | SELL | -2.98% | 101.43K | Jul 03 | View |
| Apr 26, 2023 | Antoinette Paone | CHIEF OPERATING OFFICER | -2.91K | $4.61 | -$13.43K | SELL | -100.00% | 0.00 | Apr 25 | View |
| Jan 27, 2023 | Antoinette Paone | CHIEF OPERATING OFFICER | -2.69K | $5.56 | -$14.98K | SELL | -100.00% | 0.00 | Jan 26 | View |
| Jan 11, 2023 | Antoinette Paone | CHIEF OPERATING OFFICER | -1.86K | $4.57 | -$8.52K | SELL | -100.00% | 0.00 | Jan 10 | View |
| Jan 10, 2023 | Phillip Samayoa | CHIEF STRATEGY OFFICER | -1.86K | $5.11 | -$9.53K | SELL | -1.91% | 95.82K | Jan 09 | View |
| Oct 28, 2022 | Antoinette Paone | CHIEF OPERATING OFFICER | -2.91K | $5.03 | -$14.66K | SELL | -100.00% | 0.00 | Oct 27 | View |
| Sep 30, 2022 | Antoinette Paone | CHIEF OPERATING OFFICER | -2.83K | $5.24 | -$14.82K | SELL | -100.00% | 0.00 | Sep 29 | View |
| Sep 20, 2022 | Charles Rowland Jr | — | 15.75K | $5.26 | $82.84K | BUY | 8.95% | 191.80K | Sep 19 | View |
| Sep 19, 2022 | Antoinette Paone | CHIEF OPERATING OFFICER | -4.61K | $5.32 | -$24.53K | SELL | -61.98% | 2.83K | Sep 15 | View |
| Sep 19, 2022 | Charles Rowland Jr | — | 50.63K | $5.46 | $276.24K | BUY | 40.37% | 176.05K | Sep 15 - Sep 16 | View |
| Sep 15, 2022 | Charles Rowland Jr | — | 24.38K | $5.22 | $127.40K | BUY | 24.13% | 125.42K | Sep 13 - Sep 14 | View |
| Mar 11, 2022 | William Donald Nicholson | — | 10.42K | $4.73 | $49.26K | BUY | 10.10% | 113.58K | Mar 09 - Mar 10 | View |
| Sep 29, 2021 | Jason Rhodes | DIRECTOR | -81.09K | $25.40 | -$2.06M | SELL | -6.49% | 1.17M | Sep 27 - Sep 29 | View |
| Sep 29, 2021 | ATLAS VENTURE ASSOCIATES X LPAtlas Venture Associates X LLCAtlas Venture Opportunity Fund I LPAtlas Venture Associates Opportunity I LLC | 10% OWNER | -81.09K | $25.40 | -$2.06M | SELL | -6.49% | 1.17M | Sep 27 - Sep 29 | View |
| Sep 24, 2021 | Jason Rhodes | DIRECTOR | -135.00K | $26.02 | -$3.51M | SELL | -10.36% | 1.17M | Sep 22 - Sep 24 | View |
| Sep 24, 2021 | ATLAS VENTURE ASSOCIATES X LPAtlas Venture Associates X LLCAtlas Venture Opportunity Fund I LPAtlas Venture Associates Opportunity I LLC | 10% OWNER | -135.00K | $26.02 | -$3.51M | SELL | -10.36% | 1.17M | Sep 22 - Sep 24 | View |
| Sep 16, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $16.33 | -$105.66K | SELL-OPTIONS | 0.00% | 198.15K | Sep 14 | View |
| Sep 14, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $15.28 | -$64.14K | SELL-OPTIONS | 0.00% | 198.15K | Sep 10 | View |
| Aug 25, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $14.81 | -$30.68K | SELL-OPTIONS | 0.00% | 198.15K | Aug 23 | View |
| Aug 11, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $13.61 | -$27.06K | SELL-OPTIONS | 0.00% | 198.15K | Aug 10 | View |
| Jul 14, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $14.81 | -$61.32K | SELL-OPTIONS | 0.00% | 198.15K | Jul 12 | View |
| Jul 12, 2021 | Douglas Kerr | CHIEF MEDICAL OFFICER | 0.00 | $15.18 | -$70.52K | SELL-OPTIONS | 0.00% | 326.56K | Jul 08 | View |
| Jun 28, 2021 | Jason Rhodes | DIRECTOR | -31.01K | $25.85 | -$801.62K | SELL | -2.39% | 1.27M | Jun 24 | View |
| Jun 28, 2021 | ATLAS VENTURE ASSOCIATES X LPAtlas Venture Associates X LLCAtlas Venture Opportunity Fund I LPAtlas Venture Associates Opportunity I LLC | 10% OWNER | -31.01K | $25.85 | -$801.62K | SELL | -98.08% | 608.00 | Jun 24 | View |
| Jun 23, 2021 | Jason Rhodes | DIRECTOR | -185.08K | $25.05 | -$4.64M | SELL | -12.74% | 1.27M | Jun 21 - Jun 23 | View |
| Jun 23, 2021 | ATLAS VENTURE ASSOCIATES X LPAtlas Venture Associates X LLCAtlas Venture Associates Opportunity I LPAtlas Venture Associates Opportunity I LLC | 10% OWNER | -185.08K | $25.05 | -$4.64M | SELL | -99.64% | 666.00 | Jun 21 - Jun 23 | View |
| Jun 17, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $16.34 | -$35.23K | SELL-OPTIONS | 0.00% | 198.15K | Jun 15 | View |
| Jun 11, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $15.91 | -$135.84K | SELL-OPTIONS | 0.00% | 198.15K | Jun 10 | View |
| May 28, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $19.32 | -$44.19K | SELL-OPTIONS | 0.00% | 198.15K | May 27 | View |
| May 12, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $15.66 | -$269.22K | SELL-OPTIONS | 0.00% | 198.15K | May 10 - May 11 | View |
| May 05, 2021 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | 0.00 | $20.14 | -$77.76K | SELL-OPTIONS | 0.00% | 0.00 | May 03 | View |
| May 05, 2021 | GEOFF MCDONOUGH | PRESIDENT AND CEO | -10.00K | $35.63 | -$356.34K | SELL | -0.69% | 1.45M | May 03 | View |
| Apr 27, 2021 | GEOFF MCDONOUGH | PRESIDENT AND CEO | -10.00K | $35.10 | -$351.00K | SELL | -0.68% | 1.46M | Apr 23 | View |
| Apr 23, 2021 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | 0.00 | $18.95 | -$71.83K | SELL-OPTIONS | 0.00% | 0.00 | Apr 22 | View |
| Apr 23, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $16.57 | -$95.85K | SELL-OPTIONS | 0.00% | 198.15K | Apr 21 - Apr 22 | View |
| Apr 20, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $14.32 | -$41.15K | SELL-OPTIONS | 0.00% | 198.15K | Apr 16 | View |
| Apr 14, 2021 | Jason Rhodes | DIRECTOR | -140.68K | $25.92 | -$3.65M | SELL | -99.57% | 608.00 | Apr 12 - Apr 14 | View |
| Apr 14, 2021 | ATLAS VENTURE ASSOCIATES X LPAtlas Venture Associates X LLC | 10% OWNER | -140.68K | $25.92 | -$3.65M | SELL | -1.52% | 9.11M | Apr 12 - Apr 14 | View |
| Apr 14, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $13.42 | -$153.85K | SELL-OPTIONS | 0.00% | 198.15K | Apr 12 | View |
| Apr 09, 2021 | ATLAS VENTURE ASSOCIATES X LPAtlas Venture Associates X LLC | 10% OWNER | -127.09K | $28.20 | -$3.58M | SELL | -1.35% | 9.25M | Apr 07 - Apr 09 | View |
| Apr 09, 2021 | Jason Rhodes | DIRECTOR | -127.09K | $28.20 | -$3.58M | SELL | -47.36% | 141.29K | Apr 07 - Apr 09 | View |
| Apr 07, 2021 | Douglas Kerr | CHIEF MEDICAL OFFICER | 0.00 | $17.63 | -$350.84K | SELL-OPTIONS | 0.00% | 326.56K | Apr 05 | View |
| Mar 12, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $17.79 | -$360.91K | SELL-OPTIONS | 0.00% | 198.15K | Mar 10 | View |
| Mar 09, 2021 | Douglas Kerr | CHIEF MEDICAL OFFICER | 0.00 | $18.02 | -$302.55K | SELL-OPTIONS | 0.00% | 326.56K | Mar 05 | View |
| Mar 05, 2021 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | 0.00 | $22.98 | -$110.37K | SELL-OPTIONS | 0.00% | 0.00 | Mar 03 | View |
| Mar 03, 2021 | GEOFF MCDONOUGH | PRESIDENT AND CEO | -10.00K | $37.58 | -$375.80K | SELL | -0.68% | 1.47M | Mar 01 | View |
| Mar 03, 2021 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | 0.00 | $21.71 | -$85.62K | SELL-OPTIONS | 0.00% | 0.00 | Mar 01 | View |
| Feb 12, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $17.60 | -$353.62K | SELL-OPTIONS | 0.00% | 198.15K | Feb 10 | View |
| Feb 10, 2021 | Douglas Kerr | CHIEF MEDICAL OFFICER | 0.00 | $18.98 | -$324.24K | SELL-OPTIONS | 0.00% | 326.56K | Feb 08 | View |
| Feb 04, 2021 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | 0.00 | $18.82 | -$71.15K | SELL-OPTIONS | 0.00% | 0.00 | Feb 02 | View |
| Jan 20, 2021 | Mark Angelino | CHIEF OPERATING OFFICER | 0.00 | $18.78 | -$212.85K | SELL-OPTIONS | 0.00% | 515.48K | Jan 15 | View |
| Jan 15, 2021 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | 0.00 | $18.84 | -$71.25K | SELL-OPTIONS | 0.00% | 0.00 | Jan 14 | View |
| Jan 15, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $16.57 | -$179.83K | SELL-OPTIONS | 0.00% | 198.15K | Jan 14 | View |
| Jan 13, 2021 | Douglas Kerr | CHIEF MEDICAL OFFICER | 0.00 | $16.09 | -$259.05K | SELL-OPTIONS | 0.00% | 326.56K | Jan 11 | View |
| Jan 13, 2021 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | 0.00 | $14.15 | -$401.48K | SELL-OPTIONS | 0.00% | 198.15K | Jan 11 | View |
| Jan 13, 2021 | William Donald Nicholson | — | 4.08K | $24.50 | $99.98K | BUY | 4.12% | 103.16K | Jan 11 | View |
| Jan 13, 2021 | Charles Rowland Jr | — | 20.41K | $24.50 | $500.00K | BUY | 25.31% | 101.03K | Jan 11 | View |
| Dec 17, 2020 | Mark Angelino | — | 0.00 | $19.79 | -$161.10K | OPTION EXERCISE | 0.00% | 515.48K | Dec 15 | View |
| Dec 14, 2020 | Matthew Stanton | — | 0.00 | $19.11 | -$390.17K | OPTION EXERCISE | 0.00% | 198.15K | Dec 10 | View |
| Jun 18, 2020 | Wellington Biomedical Innovation Master Investors Cayman I LP | — | 2.11M | $19.00 | $20.90M | DERIVATIVE CONVERSION | ∞ | 2.11M | Jun 16 | View |
| Jun 18, 2020 | Invus Public Equities LPPascal MinneSCA International ArtalSA Management International ArtalSA Group ArtalSA WestendWestend Administratiekantoor StichtingArtal Treasury LtdInvus Public Equities Advisors LLC | — | 2.81M | $19.00 | $15.20M | DERIVATIVE CONVERSION | ∞ | 2.81M | Jun 16 | View |
| Jun 18, 2020 | Charles Rowland Jr | — | 80.63K | $19.00 | $570.00K | DERIVATIVE CONVERSION | ∞ | 80.63K | Jun 16 | View |
| Jun 18, 2020 | Casdin Capital LLCEli Casdin | — | 1.61M | $19.00 | $12.35M | DERIVATIVE CONVERSION | ∞ | 1.61M | Jun 16 | View |
| Jun 17, 2020 | Zone Healthcare Holdings LLCFARALLON CAPITAL MANAGEMENT LLCCCA PARTNERS FARALLONPhilip DreyfussMichael FischRICHARD FRIEDDavid KimMichael LinnRAJIV PATELThomas Roberts Jr | — | 1.92M | $19.00 | $7.60M | DERIVATIVE CONVERSION | 100.00% | 3.84M | Jun 16 | View |
| Jun 17, 2020 | William SeyboldAndrew SpokesJohn WarrenMARK WEHRLY | — | 1.92M | $19.00 | $7.60M | DERIVATIVE CONVERSION | 100.00% | 3.84M | Jun 16 | View |
| Jun 16, 2020 | James FlynnDeerfield Mgmt LPDEERFIELD MANAGEMENT COMPANY LP SERIES CDEERFIELD PARTNERS LP | — | 1.19M | $19.00 | $4.28M | DERIVATIVE CONVERSION | ∞ | 1.19M | Jun 16 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.